Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
Funding opportunity for advancing nanotechnology-based cancer treatments to improve effectiveness through innovative nanoparticle designs and cargos.
Funder: National Institutes of Health
Due Dates: May 19, 2025 | November 17, 2025 | May 18, 2026 | November 16, 2026 | May 17, 2027 | November 15, 2027
Funding Amounts: Up to $475,000 direct costs per year, maximum 4 years per project (R01 mechanism).
Summary: Supports advanced pre-clinical research to translate nanotechnology-based cancer diagnostics and therapeutics toward clinical application.
Key Information: Clinical trials are not allowed; projects must focus on translational readiness and require strong preliminary data.
Description
This opportunity, offered by the National Cancer Institute (NCI) at NIH, funds advanced pre-clinical research to accelerate the translation of nanotechnology-based cancer interventions—such as nanoparticle formulations and nano-devices—toward clinical application. The program aims to mature experimental nanomedicines and diagnostics that demonstrate strong potential to improve cancer treatment or diagnosis effectiveness, due to innovative nanoparticle/nano-device design and/or the therapeutic or diagnostic cargo delivered.
Projects should address highly relevant cancer clinical objectives and unmet needs, with the expectation that successful outcomes will position the technology for further development through NCI’s Experimental Therapeutics (NExT) and other translational programs. Multidisciplinary teams, including clinical expertise, are strongly encouraged.
